Navigation Links
Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
Date:10/29/2007

DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that two posters describing significant preclinical studies performed by Access collaborators at two prominent institutes in France, were presented last week at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications One poster provides results of additional studies of the mechanism of ProLindac's anticancer activity, while the second poster demonstrates the potential benefits for cancer therapy of combining ProLindac with other anticancer agents.

"These studies, which are a continuation of work presented at the AACR annual meeting earlier this year, provide further support to our belief that ProLindac has the potential to become an important tool in the fight against cancer" stated David P. Nowotnik, Access' Senior Vice President Research and Development. "One poster shows that the cytotoxicity of ProLindac in a panel of cancer cell lines is greater than that found for either oxaliplatin or cisplatin, while the second poster demonstrates that combinations of ProLindac with certain other anticancer compounds produces cytotoxic effects which are greater than is produced by use of the drugs individually."

In addition, the studies reaffirmed that ProLindac becomes more effective in the lowered pH environment of many tumors by showing that the formation of cancer-killing platinum-DNA adducts increases in tumor cells which are exposed to lower pH conditions. Exposure to ProLindac also resulted in tumor cell cycle arrest at a phase of the cycle where the tumor cell is more susceptible to damage. These effects can lead to programmed death (apoptosis) of the tumor cell. A synergistic effect of ProLind
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Tenn., Dec. 14 Embarrassing and sometimes uncomfortable ... National researchers are taking note of a new ... approval process. The Knoxville-based company, EDP Biotech ... revolutionary, ColoMarker, an affordable medical device doctors can use ... sample. "When you consider that 30% of colon ...
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
(Date:12/14/2009)... 14 Corgenix Medical Corporation (OTC ... marketer of diagnostic test kits, and BG ... sciences company, announced today a supply agreement ... products in enzyme-linked immunosorbent assay (ELISA) microtiter ... is seeking regulatory clearance in the United ...
Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Drug ads ineffective for boosting sales could cost taxpayers 3A UBC Harvard study 61994 1Drug ads ineffective for boosting sales could cost taxpayers 3A UBC Harvard study 61994 2The cause behind the characteristic shape of a long leaf revealed 10881 1The cause behind the characteristic shape of a long leaf revealed 10881 2Water droplets direct self assembly process in thin film materials 14949 1Water droplets direct self assembly process in thin film materials 14949 2
... SAN FRANCISCO, Oct. 26 Semafore Pharmaceuticals Inc.,announced ... at the 2007,AACR-NCI- EORTC International Conference in San ... synergistic effects,with certain standard chemotherapy agents in vitro ... showed significant (p<0.001) synergistic growth,inhibition of prostate cancer ...
... 25 Paratek Pharmaceuticals, Inc. announced,today that ... a $40 million private,financing. Aisling Capital led ... D.E. Shaw and Boston Life Science Venture ... BioVentures, BioFund,Ventures, HBM BioVentures, Lombard Odier Darier ...
Other Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 2Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 3Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections 4
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) expresses its ... Teamsters Local 929 and the American Red Cross ... depends on skilled workers to provide clean, safe ... products such as clotting factor for use in ... The Division of Blood Services at the American ...
(Date:12/14/2009)... Exercise benefited men whose disease had been treated, hadn,t ... -- Exercise appears to reduce the risk of death ... study, which began in January 1986, included 668 men ... stage III colon cancer that had not spread (nonmetastatic ... that asked them about any new cancer and disease ...
(Date:12/14/2009)... study finds, , , MONDAY, Dec. 14 (HealthDay News) -- ... morning without a cup or two of java: Coffee ... type 2 diabetes. , That,s the conclusion of ... you drink, the lower your risk of diabetes. Every ... reduction in the risk of diabetes, the researchers said. ...
(Date:12/14/2009)... poorly treated and highly stigmatized, according to psychiatrists ... M.D., Ph.D. So these Washington University physicians have ... In "Demystifying Psychiatry," Zorumski and Rubin, who have ... patients and helping patient families, say some of ... result from a lack of understanding psychiatry and ...
(Date:12/14/2009)... lower rates for meth and smoking, but concerns ... (HealthDay News) -- Fewer teenagers are using methamphetamine, ... abuse of prescription drugs remains high, U.S. health ... newer drugs, such as the hallucinogenic salvia leaf ... for treatment of attention-deficit hyperactivity disorder (ADHD), appear ...
Breaking Medicine News(10 mins):Health News:HFA Voices Blood Safety Concerns 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 4
... Oct. 10 A senior citizen,soared over the 13,500-foot peaks ... was taken by retired WW II B-25 pilot Roy,Heden. The ... line of Silverado Senior Living, where Heden was a patient.,Called ... cards and it has helped,many realize a special activity at ...
... careful screening for these patients, researcher says , , FRIDAY, ... syndrome have a 75 percent higher risk for developing ... suggests. , "Metabolic syndrome is a conglomeration of three ... prognosis for certain illnesses, including a number of cancers," ...
... Center (BMC) has received a $5,807,469 grant over five years ... Boston Claude D. Pepper Older Americans Independence Center. BMC,s Pepper ... country. , The Claude D. Pepper Older Americans Independence ... the late U.S. senator from Florida. During his five decades ...
... A nationally recognized faculty will,present the very ... the multimedia course "Optimizing Adjuvant Breast Cancer,Strategies: From ... Month., It is challenging for practicing oncologists ... to date on the latest patient care,advances. This ...
... a thorough review of multiple,competitive bids, the Virginia ... selected Policy Studies Inc. (PSI) to operate its,full-service ... districts.,PSI is a leading provider of health and ... at approximately $7 million annually and,will run through ...
... study says , , THURSDAY, Oct. 9 (HealthDay News) -- People ... and tolerate sorafenib drug therapy equally well, a new study ... Journal of the National Cancer Institute , counters the ... therapy and are more likely to suffer side effects than ...
Other Medicine News:Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:Boston Medical Center receives $5.8m grant 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2Health News:PSI Selected to Operate Virginia's Child Support Program in Chesapeake and Hampton 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: